first file is the actual assignment to answer all the questions to the theranos case. the last 2 files are the info you need to complete the questions to the first file
University of the Incarnate Word Acct 6348 Advanced Audit Research Theranos Case 1. Why did the SEC take action against Elizabeth Holmes and Theranos? 2. How much money did Theranos raise and what product were they developing? 3. What function did Theranos’s “proprietary analyzer” claimed to perform? 4. What person or group of investors controlled the company? 5. When was the company founded and by what person or group of investors? How long was the company in operation? 6. Why did Sunny Balwani join the company? 7. How much blood did Theranos claim was required to perform a blood test? How many different types of blood tests could they perform as compared to their claims? What machine(s) did they use to perform the tests? University of the Incarnate Word Acct 6348 Advanced Audit Research Theranos Case 8. Describe the financial projections Theranos provided to investors? What were the claims made by the company? 9. How did the projections compare to the actual financial results? 10. What additional due diligence could investors have performed to protect their investment? 11. In 2015, Theranos had ~ 800 employees. In your opinion, why do you think the fraud perpetuated for so many years? 12. In your opinion, who was responsible for the fraud and the downfall of the company? Why? 13. In your opinion, was there an ethical breakdown? If so, why and who was responsible? 1 This CEO is out for blood Theranos founder and CEO Elizabeth Holmes Photograph by Joe Pugliese for Fortune By Roger Parloff June 12, 2014 2 In the fall of 2003, Elizabeth Holmes, a 19-year-old sophomore at Stanford, plopped herself down in the office of her chemical engineering professor, Channing Robertson, and said, “Let’s start a company.” Robertson, who had seen thousands of undergraduates over his 33-year teaching career, had known Holmes just more than a year. “I knew she was different,” Robertson told me in an interview. “The novelty of how she would view a complex technical problem–it was unique in my experience.” Holmes had then just spent the summer working in a lab at the Genome Institute in Singapore, a post she had been able to fill thanks having learned Mandarin in her spare hours as a Houston teenager. Upon returning to Palo Alto, she showed Robertson a patent application she had just written. As a freshman, Holmes had taken Robertson’s seminar on advanced drug-delivery devices–things like patches, pills, and even a contact-lens-like film that secreted glaucoma medication–but now she had invented one the likes of which Robertson had never conceived. It was a wearable patch that, in addition to administering a drug, would monitor variables in the patient’s blood to see if the therapy was having the desired effect, and adjust the dosage accordingly. “I remember her saying, ‘And we could put a cellphone chip on it, and it could telemeter out to the doctor or the patient what was going on,’” Robertson recounts. “And I kind of kicked myself. I’d consulted in this area for 30 years, but I’d never said, here we make all these gizmos that measure, and all these systems that deliver, but I never brought the two together.” Still, he balked at seeing her start a company before finishing her degree. “I said, ‘Why do you want to do this?’ And she said, ‘Because systems like this could completely revolutionize how effective health care is delivered. And this is what I want to do. I don’t want to make an incremental change in some technology in my life. I want to create a whole new technology, and one that is aimed at helping humanity at all levels regardless of geography or ethnicity or age or gender.’” That clinched it for him. “When I finally connected with what Elizabeth fundamentally is,” he says, “I realized that I could have just as well been looking into the eyes of a Steve Jobs or a Bill Gates.” 3 Theranos can run as many as 70 tests on a sample this size, obtained by pricking a finger . Photograph by Drew Kelly for Fortune With Robertson’s blessing, Holmes started her company and, a semester later, dropped out to pursue it full-time. Now she’s 30, and her private, Palo Alto-based corporation, called Theranos–the name is an amalgam of the words “therapy” and “diagnosis”–has 500 employees and has raised more than $400 million from equity sales to investors who have effectively valued the company at more than $9 billion. All these numbers, confirmed to me by an outside director, are being published here for the first time. Though Theranos is largely unknown even in Silicon Valley, that is about to change. “This is about being able to do good,” Holmes says to me about her company. “And it’s about being able to change the health care system through what we believe this countr y 4 does so well, which is innovation and creativity and the ability to conceive of technology that can help solve policy challenges.” At first glance it’s hard to see the connection between the patch that wowed Robertson and what Theranos does now. But as we will see, to Holmes they are simply different “embodiments” of the same core insights. Theranos today is a potentially highly disruptive upstart in America’s $73 billion diagnostic-lab industry, which performs nearly 10 billion tests a year and is estimated to provide the basis for about 70% of doctors’ medical decisions. Medicare and Medicaid each pay roughly $10 billion annually on reimbursements for these tests. Theranos runs what’s called a high-complexity laboratory, certified by the federal Centers for Medicare & Medicaid Services (CMS), and it is licensed to operate in nearly every state. It currently offers more than 200–and is ramping up to offer more than 1,000–of the most commonly ordered blood diagnostic tests, all without the need for a syringe. Theranos’s tests can be performed on just a few drops of blood, or about 1/100th to 1/1,000th of the amount that would ordinarily be required–an extraordinary potential boon to frequently tested hospital patients or cancer victims, the elderly, infant s, children, the obese, those on anticoagulants, or simply anyone with an aversion to blood draws. Theranos phlebotomists–technicians licensed to take blood–draw it with a finger stick using a patented method that minimizes even the minor discomfort involved with that procedure. (To me, it felt more like a tap than a puncture.) The Theranos “wellness center” at the Walgreen’s drugstore in down town Palo Alto. Theranos’s prices for tests are often a half to a quarter of independent lab prices and a quarter to a tenth of hospital lab prices. Photograph by Drew Kelly for Fortune The company has performed as many as 70 different tests from a single draw of 25 to 50 microliters collected in a tiny vial the size of an electric fuse, which Holmes has dubbed a “nanotainer.” Such a volley of tests with conventional techniques would require numerous tubes of blood, each containing 3,000- to 5,000-microliter samples. The fact that Theranos’s technology uses such microscopic amounts of blood should eventually allow physicians far greater latitude when ordering so-called reflex tests than they have previously enjoyed. With reflex testing, the physician specifies that if a certain 5 test comes up abnormal, the lab should immediately perform follow-up tests on the same sample to pinpoint the cause of the abnormality. Reflex testing saves patients the time, inconvenience, cost, and pain of return doctor visits and additional blood draws. The results of Theranos’s tests are available within hours–often matching the speed of emergency “stat” labs today, though stat labs, which are highly inefficient, can usually perform only a limited menu of maybe 40 tests. Most important, Theranos tests cost less. Its prices are often a half to a quarter of what independent labs charge, and a quarter to a 10th of what hospital labs bill, with still greater savings for expensive procedures. Such pricing represents a potential godsend for the uninsured, the insured with high deductibles, insurers, and taxpayers. The company’s prices are set to never exceed half the Medicare reimbursement rate for each procedure, a fact that, with widespread adoption, could save the nation billions. The company also posts its prices online, a seemingly obvious service to consumers, but one that is revolutionary in the notoriously opaque, arbitrary, and disingenuous world of contemporary health care pricing. Precisely how Theranos accomplishes all these amazing feats is a trade secret. Holmes will only say–and this is more than she has ever said before–that her company uses “the same fundamental chemical methods” as existing labs do. Its advances relate to “optimizing the chemistry” and “leveraging software” to permit those conventional methods to work with tiny sample volumes. 6 Laboratory scientists perform biochemical experiments in a Theranos R&D lab in Palo Alto. Photograph by Drew Kelly for Fortune The scale of Theranos’s operations now is modest. Its phlebotomists currently take physician-ordered blood draws (and saliva, urine, feces, and other samples) at col lection centers the company operates at its headquarters in Palo Alto and at 21 Walgreens –one in Palo Alto and the rest in Phoenix. But these are only the advance guard in a gradual national rollout that Walgreens committed to last September; it plans to establish Theranos outposts in a substantial percentage of its 8,200 drugstores in all 50 states. It is the first step in Holmes’s audacious plan to place a Theranos center within five miles of almost every American and within one mile of every city dweller. Walgreens CEO Greg